$RGNT

Regentis Biomaterials (NYSE American: RGNT) priced a $6.5 million private placement with accredited and institutional investors at $3.50 per ordinary share, plus accompanying warrants (or $3.4999 per pre-funded warrant). The company will issue 1,857,143 shares (or pre-funded warrants) and warrants to buy 1,857,143 shares. Pre-funded warrants are exercisable at $0.0001; ordinary warrants at $4.20 for five years. Net proceeds will fund its GelrinC pivotal trial, FDA pre-market approval preparation

Regentis Biomaterials (NYSE: RGNT) shares moved sharply after the company filed a Form 6-K with the SEC, saying it requested withdrawal of its Form F-1 registration statement and decided not to pursue the related public offering. The stock rose 506.45% to $9.40 intraday, then fell 9.15% to $8.54 in after-hours.

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

Regentis Biomaterials (NYSE: RGNT) has filed an F-1 registration statement to sell 3,333,334 Ordinary Shares at an assumed public offering price of $3.00 per share. The company is developing GelrinC, a regenerative medicine product for articular knee cartilage repair, which is currently undergoing a pivotal clinical trial. Regentis aims to use the net proceeds from this offering for further clinical development of GelrinC, research and development activities, operational readiness, and European market entry.